Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?
Stéphane Dalle, M. Beylot‐Barry, Martine Bagot, et al.
British Journal of Dermatology (2009) Vol. 162, Iss. 1, pp. 74-79
Closed Access | Times Cited: 155

Showing 1-25 of 155 citing articles:

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju, Andrew A. Lane, Kendra Sweet, et al.
New England Journal of Medicine (2019) Vol. 380, Iss. 17, pp. 1628-1637
Open Access | Times Cited: 341
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study
Livio Pagano, Caterina Giovanna Valentini, Alessandro Pulsoni, et al.
Haematologica (2012) Vol. 98, Iss. 2, pp. 239-246
Open Access | Times Cited: 304
Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches
Livio Pagano, Caterina Giovanna Valentini, Sara Grammatico, et al.
British Journal of Haematology (2016) Vol. 174, Iss. 2, pp. 188-202
Open Access | Times Cited: 177
Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients
Fanny Julia, Tony Petrella, M. Beylot‐Barry, et al.
British Journal of Dermatology (2013) Vol. 169, Iss. 3, pp. 579-586
Closed Access | Times Cited: 173
Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation
Damien Roos‐Weil, Sascha Dietrich, Ariane Boumendil, et al.
Blood (2012) Vol. 121, Iss. 3, pp. 440-446
Open Access | Times Cited: 159
Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications
Armin G. Jegalian, Nataliya P. Buxbaum, Fabio Facchetti, et al.
Haematologica (2010) Vol. 95, Iss. 11, pp. 1873-1879
Open Access | Times Cited: 159
Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm
Juliane Menezes, Francesco Acquadro, Michele S. Wiseman, et al.
Leukemia (2013) Vol. 28, Iss. 4, pp. 823-829
Open Access | Times Cited: 155
Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion
Marco Lucioni, Francesca Novara, Giacomo Fiandrino, et al.
Blood (2011) Vol. 118, Iss. 17, pp. 4591-4594
Open Access | Times Cited: 147
Blastic Plasmacytoid Dendritic Cell Neoplasms
Fanny Julia, Stéphane Dalle, Gérard Duru, et al.
The American Journal of Surgical Pathology (2014) Vol. 38, Iss. 5, pp. 673-680
Closed Access | Times Cited: 129
Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm
Tomohiro Aoki, Ritsuro Suzuki, Yachiyo Kuwatsuka, et al.
Blood (2015) Vol. 125, Iss. 23, pp. 3559-3562
Open Access | Times Cited: 124
Neoplasms derived from plasmacytoid dendritic cells
Fabio Facchetti, Marta Cigognetti, Simona Fisogni, et al.
Modern Pathology (2016) Vol. 29, Iss. 2, pp. 98-111
Open Access | Times Cited: 121
Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm
Albrecht Stenzinger, Volker Endris, Nicole Pfarr, et al.
Oncotarget (2014) Vol. 5, Iss. 15, pp. 6404-6413
Open Access | Times Cited: 90
Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC) in Elderly Patients: Results of a Treatment Algorithm Employing Allogeneic Stem Cell Transplantation with Moderately Reduced Conditioning Intensity
Sascha Dietrich, Mindaugas Andrulis, Ute Hegenbart, et al.
Biology of Blood and Marrow Transplantation (2011) Vol. 17, Iss. 8, pp. 1250-1254
Closed Access | Times Cited: 86
Blastic Plasmacytoid Dendritic Cell Neoplasm: Update on Molecular Biology, Diagnosis, and Therapy
Wasif Riaz, Ling Zhang, Pedro Horna, et al.
Cancer Control (2014) Vol. 21, Iss. 4, pp. 279-289
Open Access | Times Cited: 81
Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature
Rahel Mathew, John M. Bennett, Jane Jijun Liu, et al.
Leukemia Research (2011) Vol. 36, Iss. 1, pp. 72-80
Closed Access | Times Cited: 81
Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation
Mohamed A. Kharfan‐Dabaja, Hillard M. Lazarus, Taiga Nishihori, et al.
Biology of Blood and Marrow Transplantation (2013) Vol. 19, Iss. 7, pp. 1006-1012
Open Access | Times Cited: 77
Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases
Fabio Facchetti, Stefano Pileri, Luisa Lorenzi, et al.
Virchows Archiv (2017) Vol. 471, Iss. 4, pp. 467-489
Closed Access | Times Cited: 72
Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm
Naveen Pemmaraju, Marina Konopleva
Blood Advances (2020) Vol. 4, Iss. 16, pp. 4020-4027
Open Access | Times Cited: 58
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, Kendra Sweet, Anthony S. Stein, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 26, pp. 3032-3036
Open Access | Times Cited: 32
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Naveen Pemmaraju, Hagop M. Kantarjian, Kendra Sweet, et al.
Blood (2022) Vol. 141, Iss. 6, pp. 567-578
Open Access | Times Cited: 30
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent
Fanny Angelot‐Delettre, Anne Roggy, Arthur E. Frankel, et al.
Haematologica (2014) Vol. 100, Iss. 2, pp. 223-230
Open Access | Times Cited: 61
Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies
Kamel Laribi, Nathalie Denizon, Anne Besançon, et al.
Biology of Blood and Marrow Transplantation (2016) Vol. 22, Iss. 8, pp. 1357-1367
Open Access | Times Cited: 57
Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5‐Azacytidine
Kamel Laribi, Nathalie Denizon, Habib Ghnaya, et al.
European Journal Of Haematology (2014) Vol. 93, Iss. 1, pp. 81-85
Closed Access | Times Cited: 55
LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis
Adam Ceroi, David Masson, Anne Roggy, et al.
Blood (2016) Vol. 128, Iss. 23, pp. 2694-2707
Open Access | Times Cited: 55
Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review
Marie JeongMin Kim, Ahmed Nasr, Bilaal Kabir, et al.
Journal of Pediatric Hematology/Oncology (2017) Vol. 39, Iss. 7, pp. 528-537
Closed Access | Times Cited: 53
Page 1 - Next Page

Scroll to top